Clinical Trials Logo

Constipation clinical trials

View clinical trials related to Constipation.

Filter by:

NCT ID: NCT06106685 Recruiting - Constipation Clinical Trials

Washed Microbiota Transplantation for Chronic Constipation in Adults

Start date: July 24, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-center, randomized, double-blind, placebo-controlled, dose-exploring clinical study to explore the safety and efficacy of washed microbiota transplantation (WMT) for patients with chronic constipation.

NCT ID: NCT06083311 Recruiting - Clinical trials for Functional Constipation

The Efficacy of a Probiotic for Functional Constipation (FC)

SLOG
Start date: October 19, 2023
Phase: N/A
Study type: Interventional

Investigate the effect of a probiotic (live bacteria) in individuals with functional constipation.

NCT ID: NCT06073262 Recruiting - Low Back Pain Clinical Trials

Investigation of Low Back Pain Level on Symptoms in Chronic Consipation

Start date: October 3, 2023
Phase:
Study type: Observational

Consipation is the most common digestive complaint in the general population

NCT ID: NCT06031025 Recruiting - Diarrhea Clinical Trials

Prevalence and Natural History of Functional Gastrointestinal Disorders Among At-risk Infants.

FUSID
Start date: May 20, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about the prevalence and characteristics of functional gastrointestinal disorders (FGID) in at risk infants (former preterm infants and those with birth asphyxia) during the first 2 years of life. The main questions it aims to answer are: - evaluate the prevalence of symptoms related to gastro-esophageal reflux (GER), of functional gastrointestinal disorders during the first 2 years of life - describe growth parameters during follow-up up to the corrected age of 2 years Participants will be assessed clinically and with a structured questionnaire based on the Rome IV criteria to describe FGID.

NCT ID: NCT05995899 Recruiting - Clinical trials for IBS - Irritable Bowel Syndrome

Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

Start date: February 6, 2024
Phase: Phase 4
Study type: Interventional

The aim of this study is to better understand how tenapanor affects the metagenomics and metabolomics of patients with irritable bowel syndrome with constipation (IBS-C). Tenapanor is the newest FDA-approved agent for IBS-C. It is a small molecule that inhibits the NHE3 receptor, leading to impaired sodium and water absorption in the intestine. Previous clinical trials comparing tenapanor to placebo showed that a 50 mg dose of tenapanor led to increased bowel movements and decreased abdominal pain. This study consists of an 8-week treatment period in which subjects will ingest one capsule of tenapanor (50 mg per dose), twice daily, and send in stool samples following 4 weeks and 8 weeks of treatment.

NCT ID: NCT05989763 Recruiting - Constipation Clinical Trials

Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis

TEA in SSc
Start date: February 17, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether transcutaneous electrical acustimulation (TEA) alters systemic sclerosis (SSc)-related colonic and anorectal physiology by enhancing autonomic nervous system (ANS) function. The study will examine the effects of TEA on slow colonic transit (SCT) and rectal hyposensitivity (RH), to examine whether TEA improves autonomic dysfunction and modulates inflammatory pathways.

NCT ID: NCT05973721 Recruiting - Pib Specific Phage Clinical Trials

Clinical Study of Phage Therapy for Chronic Constipation Efficacy and Safety

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

The overall aim was to evaluate the efficacy of PiB-specific phages for the treatment of refractory constipation through clinical studies, primarily for the publication of scientific papers and to guide the development of phage therapies. The purpose of this study will be subdivided into three aspects from three aspects: target exposure level, target occupation, and functional effects after acting on the target, including:1) The distribution of PIB phage in the intestine of patients with refractory constipation;2) The killing effect of PIB phage on PIB bacteria in refractory constipation patients;And 3) therapeutic effect of PIB phage on patients with refractory constipation.

NCT ID: NCT05910021 Recruiting - Clinical trials for Urinary Incontinence

Early Safety of Resection Recopy and Sacrocolpopexy

RRPSCPcomb
Start date: February 1, 2020
Phase:
Study type: Observational

Obstructive defecation syndrome (ODS) defines a disturbed defecation process frequently associated with pelvic organ prolapse (POP) in women. It substantially compromises quality of life and conservative treatment options are limited. In cases surgery is required the interventions are characterized by individual approaches. Laparoscopic resection rectopexy (L-RRP) combined with laparoscopic sacrocolpopexy (L-SCP) was established in an interdisciplinary setting.

NCT ID: NCT05895877 Recruiting - Constipation Clinical Trials

Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation

Start date: December 21, 2021
Phase: Phase 3
Study type: Interventional

This is a double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of Goofice® in patients with chronic constipation.

NCT ID: NCT05833191 Recruiting - Constipation Clinical Trials

Efficacy of Different Nerve Stimulation Methods in Individuals With Chronic Constipation

Start date: April 15, 2023
Phase: N/A
Study type: Interventional

Constipation is the most common digestive complaint in the general population. Normal stool frequency ranges from at least three times a week to a maximum of two times a day. Constipation can be classified into three main groups as constipation with normal transit time, constipation with slow transit time and dyssynergic defecation disorders.